Shift Your Body Clock: Amber Glasses vs. Melatonin

You may not need an expensive dim-light melatonin onset (DLMO) test to begin shifting a delayed body clock earlier. In a small 2024 randomized trial, adults with delayed sleep-wake phase disorder improved similarly whether they timed 0.5 mg melatonin from a saliva-based DLMO measurement or from a simple estimate: five hours before their habitual sleep onset.

That is useful, but it is not a license to treat every late bedtime with a supplement and a pair of orange glasses. The trial bundled melatonin with evening dim light and a time-in-bed schedule, involved only 40 people, and did not improve total sleep time or Pittsburgh Sleep Quality Index scores. It suggests a practical starting point for delayed sleepers, not a universal cure for insomnia.

A lab test did not outperform a sleep-based timing rule

DLMO is the standard biological marker of circadian phase. Under dim light, researchers collect repeated saliva samples to identify when melatonin begins to rise. It is informative and inconvenient: collection takes time, controlled light conditions, and money. Wearable-based methods can estimate phase, but their errors can approach an hour or more in irregular real-world schedules. A 2021 study of college students reported mean DLMO estimation errors of about 1.3 hours even with a classification approach using activity and light data.

The more encouraging result came from Swanson et al.'s 2024 randomized trial. Researchers enrolled 40 adults with delayed sleep-wake phase disorder and assigned 20 to take 0.5 mg melatonin three hours before measured salivary DLMO. The other 20 took the same dose five hours before habitual sleep onset measured by actigraphy. Both groups also followed evening dim-light reduction and time-in-bed scheduling for four weeks.

Both groups showed statistically significant within-group advances in DLMO, earlier sleep onset and offset on actigraphy and diaries, greater morningness on the Morningness-Eveningness Questionnaire, and better PROMIS sleep disturbance and sleep-related impairment scores after the study's Bonferroni correction threshold of p<0.004. The group-by-visit comparisons were all non-significant at that threshold (all p>0.004). In plain terms, the trial found no evidence that laboratory-guided timing produced better outcomes than the behavioral rule.

The wording matters. This was not a formal, adequately powered non-inferiority trial. The authors call the findings preliminary, and the publication does not report absolute phase-shift magnitudes, confidence intervals, or within-group effect sizes. "No statistically significant difference" can mean the approaches truly perform similarly, or that 20 people per group cannot reliably reveal a meaningful difference. Still, the result makes the five-hours-before-usual-sleep-onset rule a reasonable low-friction option for many people with a delayed schedule.

Melatonin here is a clock cue, not a sleeping pill

At 0.5 mg, melatonin is being used as a chronobiotic: a signal intended to move circadian timing. The timing is the treatment. In the Swanson trial, the laboratory-guided dose came three hours before DLMO, which places it before the body's endogenous melatonin rise. Taking melatonin near bedtime may make someone feel sleepy, but that is a different question from whether it advances their clock.

Results from a separate clinical population support the phase-advance mechanism. In a three-week randomized trial of 51 adults with ADHD and delayed sleep phase syndrome, van Andel et al. (2021) found that 0.5 mg melatonin, scheduled three hours before each participant's DLMO and advanced weekly, moved DLMO earlier. The study also reported improved ADHD symptom scores. These were adults with both ADHD and delayed sleep phase syndrome, so the functional results should not be assumed to apply to every delayed sleeper.

For people whose sleep onset is extremely late—past roughly 4 or 5 AM—the heuristic deserves more caution. The gap between sleep onset and DLMO may differ enough that five hours before sleep onset misses the phase-advance window. Clinical guidance or direct phase assessment earns its keep when the schedule is far outside the usual range.

Amber glasses have better evidence for falling asleep faster

Blue-blocking glasses target the other side of the evening equation: light. Short-wavelength light activates melanopsin-containing intrinsically photosensitive retinal ganglion cells, which feed light information to the circadian system. Evening light can suppress melatonin and push circadian timing later; amber lenses reduce the short-wavelength light reaching that pathway.

A 2021 systematic review by Hester et al. examined 16 randomized controlled trials involving 453 participants across sleep disorders, jet lag, and shift-work schedules. It found substantial evidence that wearing blue-blocking glasses in the evening reduces sleep-onset latency. That is the strongest practical claim for the glasses: they may help you fall asleep sooner.

The review did not provide a pooled number of minutes saved, a standardized effect size, or an I² heterogeneity statistic. Lens spectra, populations, and outcome measures varied across trials. So a claim that glasses shave a precise number of minutes off sleep onset would be marketing with a lab coat on.

Duration also matters. A 2022 experimental study by St Hilaire et al. found that human circadian phase resetting and melatonin suppression respond to light spectra differently as exposure duration changes. A few minutes in amber lenses is not physiologically equivalent to wearing them through the evening. Current randomized evidence does not establish a validated start time or minimum number of hours, but extended evening use is more consistent with the mechanism than putting them on while brushing your teeth.

Mood claims remain preliminary

The Hester review also included studies in major depression and postpartum depression, but their results conflicted. Blue-blocking glasses may help some sleep-related mood symptoms, yet the evidence does not establish them as a treatment for depression or postpartum depression. A faster sleep onset is a specific outcome; it does not automatically become a psychiatric intervention because the lenses are orange.

Should you combine glasses and melatonin?

The two tools act through different inputs: melatonin signals through receptors involved in circadian timing, while reducing evening short-wavelength light changes the light signal reaching the clock. That makes the pairing plausible, but plausibility is not an effect estimate.

In the ADHD and delayed sleep phase syndrome research, van Andel et al. (2022) found that adding morning bright-light therapy to melatonin chronotherapy did not provide additional circadian benefit over melatonin alone. The intervention was not amber glasses, so it does not answer the glasses-plus-melatonin question directly. It does show why distinct mechanisms should not be assumed to stack neatly in real life.

The practical priority is consistency. If you use the behavioral melatonin schedule, anchor it to your current habitual sleep onset and reassess when your schedule changes materially. Circadian phase shifts with season, weekly routine, chronotype, and real-world light exposure. In a within-person study of 33 adults, Zerbini et al. (2021) found that DLMO and sleep timing were about an hour earlier in summer than winter.

What the evidence supports tonight

• If you have a consistently delayed sleep schedule, 0.5 mg melatonin about five hours before your usual sleep onset is supported by one preliminary four-week trial as a practical alternative to lab-timed dosing.
• Use evening dim light alongside that schedule, because the central trial tested the package rather than melatonin alone.
• Amber blue-blocking glasses have randomized-trial support for reducing sleep-onset latency. Wear them for a meaningful portion of the evening, while recognizing that research has not identified an exact best duration.
• Do not expect a phase advance to add sleep hours automatically. In the 2024 trial, neither total sleep time nor Pittsburgh Sleep Quality Index scores improved significantly.
• Do not count on combination therapy to multiply results. No trial here compares glasses alone, melatonin alone, and both together, and a bright-light-plus-melatonin trial found no added circadian benefit.

If your goal is an earlier body clock, the best-supported low-cost experiment is disciplined timing: a low melatonin dose well before your usual sleep onset, less stimulating light in the evening, and a schedule you can repeat. The evidence supports moving timing. It does not promise longer sleep, better mood, or a clock that ignores Saturday night.

Morning light may also help advance circadian timing. A 2026 review by López-Velasco et al. describes preliminary evidence that morning light can shift melatonin rhythms within a day, but this evidence base contains no head-to-head trial against amber glasses or low-dose melatonin in adults with delayed sleep-wake phase disorder. For now, the no-lab melatonin rule and evening light reduction are practical tools with real limits, not a replacement for clinical evaluation when sleep timing is severely delayed or disabling.